toxylact: a06ab03 dantron

The first professional lActological database in the word

Dantron (ATC A06AB03) is a contact stimulant laxative that enhances colonic motility, but its use in breastfeeding is generally discouraged due to carcinogenicity concerns and lack of safety data in lactation.medpedia.framar+2

Drug class and composition

Dantron (also known as 1,8‑dihydroxyanthraquinone, chrysazin) belongs to the ATC class A06AB03 “contact laxatives” within “drugs for constipation.”wikipedia+3
It is an anthraquinone derivative that exerts a direct irritating effect on the colonic mucosa, classified as a stimulant laxative rather than a bulk‑forming or osmotic agent.medpedia.framar+1

Mechanism of action

Dantron increases intestinal motility by stimulating sensory nerve endings in the colonic mucosa, thereby enhancing peristalsis and facilitating defecation.gsrs-dev-public.ncats+1
This local action shortens colonic transit time and reduces water reabsorption, leading to softer stools and improved bowel emptying.wikipedia+1

Indications and therapeutic use

Historically, dantron has been used in adults with chronic constipation and in patients with hard stools to restore more regular defecation.medicamente+1
In many markets its use has become restricted or discontinued because of safety concerns; where available, it is generally reserved for short‑term treatment of constipation and sometimes in combination preparations for bowel evacuation.precision.fda+2

Dosage and administration

The defined daily dose in the ATC/DDD index for dantron is 50 mg orally in adults, reflecting typical maintenance use in chronic constipation.atcddd.fhi
Clinically, dantron has been given as oral tablets and, in some settings, rectal enemas, but current product availability varies by country and is often limited.drugcentral+2

Contraindications and precautions

Dantron is contraindicated in patients with known hypersensitivity, suspected or confirmed intestinal obstruction, acute surgical abdominal conditions, and severe inflammatory bowel disease.drugcentral+1
In the United States and some other jurisdictions dantron has not been accepted for use because of evidence of carcinogenic effects in animal studies, which has led to regulatory withdrawal or strong restrictions.drugfuture+2

Adverse effects

Reported adverse reactions include abdominal pain, diarrhea, headache, hypotension, arrhythmias, allergic reactions and red discoloration of urine (“pseudohaematuria”).synapse.patsnap+2
Dantron and related anthraquinones are associated with pigment deposition in colonic mucosa (melanosis coli) with prolonged use, and long‑term exposure has raised concerns regarding tumorigenesis in preclinical models.drugfuture+1

Carcinogenicity and regulatory status

Preclinical studies have shown dantron to be carcinogenic in rodents, particularly causing intestinal and hepatic tumors, which underpins its limited approval status.wikipedia+1
Regulatory agencies in several countries have subsequently withdrawn dantron‑containing products or restricted them to specific indications and short‑term use, favoring safer laxatives for chronic constipation.mayoclinic+2

Use in special populations

In children, dantron is generally avoided because of its stimulant mechanism, potential for dehydration, and theoretical carcinogenic risk; safer alternatives such as polyethylene glycol or docusate are preferred.mayoclinic+1
In older adults, chronic dantron therapy is discouraged due to cumulative toxicity, melanosis coli, and the availability of laxatives with better long‑term safety profiles.synapse.patsnap+1

Toxicological profile

At therapeutic doses dantron mainly causes gastrointestinal irritation, but overdose can lead to severe diarrhea, electrolyte disturbances, hypotension, and cardiac rhythm abnormalities.medpedia.framar+1
Systemic exposure has been linked to hepatic enzyme changes in animal studies, and its anthraquinone structure is considered a contributing factor in DNA‑damaging and carcinogenic potential.drugfuture+1

Lactation safety considerations

Evidence on dantron transfer into human breast milk and infant exposure is extremely limited, with only sparse case reports and no robust pharmacokinetic studies.hero.epa+1
Given its carcinogenicity in animals, lack of human safety data, and the availability of safer laxatives, expert sources generally advise avoiding dantron during breastfeeding and selecting alternatives with established lactation compatibility.hero.epa+2

For constipation in breastfeeding mothers, osmotic agents such as polyethylene glycol and stool softeners like docusate are widely considered compatible with lactation and are preferred over stimulant anthraquinones.hero.epa+1
Non‑pharmacological measures (adequate fluid intake, dietary fiber, physical activity) should be optimized first, and if drug therapy is needed, reference sources such as LactMed and national prescribing services recommend safer choices than dantron.ncbi.nlm.nih+2

Clinical positioning in toxicological‑lactological practice

In a toxicological‑lactological context, dantron should be classified as a high‑concern laxative for breastfeeding mothers because of carcinogenic risk and insufficient infant safety data.hero.epa+1
Risk–benefit assessment strongly favors avoidance in lactation, and dantron‑containing products should not be first‑line for chronic constipation in the general population when safer agents are available.gsrs-dev-public.ncats+1

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.